REMATIQ Raises €5.4 Million Seed Round to Transform MedTech Compliance with AI
AI cuts regulatory workload by up to 90%
Regulatory requirements are among the biggest challenges in the MedTech industry: more than 40% of R&D teams' time is spent on manual regulatory tasks – time that could be used for innovation. REMATIQ’s AI-powered platform analyzes global regulatory documents and instantly provides actionable requirements. These are integrated directly into development and quality processes, reducing documentation efforts by up to 90% and significantly lowering the risk of non-compliance. REMATIQ’s mission is to bring life-saving innovations to market faster and more safely.
To that end, REMATIQ collaborates with leading MedTech companies worldwide. “The volume and complexity of international regulations continue to grow. We feel this every day – in development, clinical evaluation, regulatory approval, and post-market surveillance. An AI-based approach to regulatory requirements management – like the one REMATIQ offers – addresses exactly the point of highest leverage,” says Mandy Blocher, Head of PLM Digitalization & Regulatory Intelligence at the B. Braun Group.
Funding to accelerate technology and scale operations
REMATIQ plans to use the new capital to further develop its AI technology, expand its engineering team, and drive international growth across Europe and the United States.
"Regulatory requirements shouldn’t slow down innovation – they should help accelerate it. With REMATIQ, we turn compliance from a hurdle into a competitive advantage”, says David Boutellier, Co-Founder & CEO of REMATIQ. “Our goal is to bring life-saving MedTech solutions – from wound care to CT scanners – to patients faster. We’re grateful to our investors for believing in this vision and supporting us in reshaping the industry."
Anton Waitz, General Partner at Project A, adds: "REMATIQ is solving a mission-critical problem. While regulatory burdens are slowing many companies down, REMATIQ offers a way to dramatically increase efficiency – without compromising on quality or safety. The team impressed us with deep industry expertise and a strong technology vision. We're excited to support them on this journey."
About REMATIQ: REMATIQ was founded in 2023 by David Boutellier and Florian Scherer. Their conviction: regulatory requirements are essential—but they should never hold back innovation. With REMATIQ, they help MedTech companies reduce regulatory complexity without sacrificing quality or safety.
The platform uses artificial intelligence to radically simplify compliance workflows during medical device development. It translates complex regulations – like MDR and FDA – into structured, actionable requirements and integrates them into companies’ existing systems. This saves up to 90% of the time typically required for regulatory documentation and coordination – freeing up engineers to focus on life-changing innovations.
REMATIQ is based in Berlin and backed by Project A Ventures, Amino Collective, and a select group of leading angel investors.
Learn more at: www.rematiq.com
